Cognitive Function in Older Adults: Worse in Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk

A Puzzling Era in Global Drug Development? Dr. Eric Ruderman offers his observation regarding a puzzling global drug development observation, at Eular 2024 in Vienna, Austria. https://t.co/A4KQovIt3u https://t.co/TQHJnSkIod

Be-GIANT cohort, 44.3% pts met definition of early axSpA (<2 yr Sxs). early axSpA had younger age and lower frequency of radiographic sacroiliitis. MDs think early disease to be more severe with higher physician global than late axSpA @synovialjoints #EULAR2024 Abstract POS0443 https://t.co/97J9tg0XZg

FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw

Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Work ability impaired in majority of axSpA measured by the WAI score. 996 pts w a mean WAI score of 31.7. Overall, 28%/43%pts were in poor/moderate work ability, older, more often obese, w/ lower education, & phys work @synovialjoints #EULAR2024 Abstract POS0437 @RheumNow https://t.co/rQ4BunCn6T

Systemic Score in AOSD to Predict Life-threatening Complications Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria. https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2

The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f

The path to new technologies in rheumatology must be beset with caution https://t.co/rostCE3UFT https://t.co/bn352RmrN8

Personalized Exercise may have Key Benefits in AxSpa At EULAR, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for people with AxSpA and severe functional limitations. https://t.co/TUP6hoLgJ4 https://t.co/t1gNQBdFzh

Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/58cJsSROsE to stay at the forefront of medical innovation. https://t.co/jbbufRQ6MW

Rituximab vs. Tocilizimab for Scleroderma: Which is Better? Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria. https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u